SCHEMBL6902220

SCHEMBL6902220

CC(=NOCCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccc(OC(C)C)nc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 14/20 0.70
FFAR1 O14842 4/20 0.47
CYP3A4 P08684 2/20 0.47
RXRA P19793 1/20 0.47
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MPC2 O95563 1/20 0.44
CYP2C8 P10632 1/20 0.44
CYP2C9 P11712 1/20 0.44
PPARA Q07869 2/20 0.44
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6902217 1.00 PPARG (0.70) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6898686 0.90 PPARG (0.73) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6898681 0.90 PPARG (0.73) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6904419 0.89 PPARG (0.72) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL6904420 0.89 PPARG (0.72) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL8305406 0.86 PPARG (0.76) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL8305416 0.86 PPARG (0.76) PPARGFFAR1CYP3A4RXRAMEN1
SCHEMBL8308611 0.86 PPARG (0.76) PPARGFFAR1CYP3A4RXRAPPARA
SCHEMBL8308613 0.86 PPARG (0.76) PPARGFFAR1CYP3A4RXRAPPARA
SCHEMBL6902809 0.83 PPARG (0.77) PPARGFFAR1CYP3A4RXRAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP claimed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US claimed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP claimed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP claimed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP claimed
EP-0919232-B1 Composition for use in the treatment and prevention of hyperuricemia SANKYO CO (JP) 2004-10-06 EP disclosed
US-6353009-B1 TREATMENT OF GOUT WITH ANTIINFLAMMATORY AGENTS SANKYO COMPANY, LIMITED (JP) 2002-03-05 US disclosed
US-6150371-A WITH THE EXCEPTION OF TYPE I DIABETES; INHIBITS INVASION OF ORGAN TISSUE BY CYTOTOXIC LYMPHOCYTES; ADMINISTERING TO A MAMMAL AN ANTIAUTOIMMUNE DISEASE AGENT BEING AN INSULIN RESISTANCE REDUCING AGENT, ANTIDIABETIC, E.G., TROGLITAZONE SANKYO COMPANY, LIMITED (JP) 2000-11-21 US disclosed
EP-0993442-A1 HYDRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-04-19 EP disclosed
EP-0953355-A1 REMEDY FOR AUTOIMMUNE DISEASES Sankyo Company, Limited (JP) 1999-11-03 EP disclosed
US-5972959-A Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1999-10-26 US disclosed
EP-0919232-A1 Composition for use in the treatment and prevention of hyperuricemia Sankyo Company Limited (JP) 1999-06-02 EP disclosed
EP-0708098-B1 Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1999-03-03 EP disclosed
WO-1999001428-A1 HYDRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-01-14 WO disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed